EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition

Kaizhen Wang, Yijiao Liu, Zhiyi Zhang, Yingxin Hu, Yuhua Zhong, Sheng Jiang iD, Xiangyu Zhang iD, Kuojun Zhang iD, Tianyu Wang iD

Journal of Medicinal Chemistry · 09.07.2026 · 69 (13) · 15510-15530

DOI: 10.1021/acs.jmedchem.6c00353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.06.2026. Verfasst von Kaizhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Nicotinamide Phosphoribosyltransferase, Cytokines, Antineoplastic Agents. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of the Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) represents a promising therapeutic strategy for cancer. However, resistance to SHP2 inhibition, mediated by multiple mechanisms, has limited the clinical efficacy of SHP2 inhibitor monotherapy. Herein, we identified that nicotinamide phosphoribosyltransferase (NAMPT) inhibition could potentially overcome resistance to SHP2 inhibition in tumor cells. Compound A4 was identified as the most potent dual inhibitor targeting SHP2 and NAMPT, exhibiting high inhibitory activity against both SHP2 and NAMPT. A4 effectively inhibited proliferation in SHP099-insensitive tumor cell lines and reversed programmed cell death ligand 1 (PD-L1)-mediated immunosuppression. Furthermore, A4 displayed significant in vivo antitumor efficacy in an MDA-MB-231 mouse model and strongly promoted in vivo antitumor immunity in a 4T1 mouse model. Our results identified A4 as a promising dual SHP2 and NAMPT inhibitor, providing a novel therapeutic strategy for overcoming resistance to allosteric SHP2 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11Nicotinamide PhosphoribosyltransferaseCytokinesAntineoplastic AgentsEnzyme InhibitorsSmall Molecule LibrariesDrug DiscoveryHumansAnimalsMiceAllosteric RegulationFemaleCell Line, TumorStructure-Activity RelationshipCell ProliferationDrug Resistance, NeoplasmMice, Inbred BALB C

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Nicotinamide PhosphoribosyltransferaseCytokinesAntineoplastic AgentsEnzyme Inhibitorsnicotinamide phosphoribosyltransferase, humanPTPN11 protein, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • School of Biomedical Engineering, Tsinghua University, Beijing 100084, China.

ORCID-Profile: Sheng Jiang, Xiangyu Zhang, Kuojun Zhang, Tianyu Wang

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Wang, K., Liu, Y., Zhang, Z., Hu, Y., Zhong, Y., Jiang, S., Zhang, X., Zhang, K., & Wang, T. (2026). Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of Medicinal Chemistry, 69(13), 15510-15530. https://doi.org/10.1021/acs.jmedchem.6c00353

Vancouver

Wang K, Liu Y, Zhang Z, Hu Y, Zhong Y, Jiang S, et al. Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of Medicinal Chemistry. 2026;69(13):15510-15530. doi:10.1021/acs.jmedchem.6c00353

BibTeX
@article{Wang2026,
  author = {Wang, Kaizhen and Liu, Yijiao and Zhang, Zhiyi and Hu, Yingxin and Zhong, Yuhua and Jiang, Sheng and Zhang, Xiangyu and Zhang, Kuojun and Wang, Tianyu},
  title = {Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {13},
  pages = {15510--15530},
  doi = {10.1021/acs.jmedchem.6c00353}
}
Kostenlos starten →